Three Metabolic Peptides, Read Skeptically

The short version

Swe Peptider is an audit, not a shop window. It reads the published literature on three peptides grouped here because they are all studied for metabolic regulation and weight management — MOTS-c, semaglutide, and tesamorelin — and it reports, compound by compound, what has actually been shown, in whom, and how solidly. A peptide is simply a short chain of amino acids, the same building blocks that make up proteins, just smaller; several of the compounds on this desk are built to mimic a hormone the body already makes.

The three peptides sit at very different points on the evidence ladder. Semaglutide has been through more than a dozen large randomized trials and carries multiple FDA approvals. Tesamorelin has one FDA approval, for a specific HIV-related condition, and everything else about it is inference. MOTS-c has essentially no human intervention trials at all — its case rests on cell and mouse work plus one observational study in dialysis patients. This site does not average those three cases into a single reassuring story. It keeps them separate, cites the primary sources, and says plainly where the evidence runs out. Nothing here is a recommended dose or a substitute for a clinician.

What are research peptides?

'Research peptide' is a marketing category more than a scientific one. It usually means a compound sold for laboratory use, without the manufacturing, purity, and clinical oversight that apply to an approved medicine. That label tells a reader almost nothing about how strong the underlying evidence actually is — some compounds sold this way have deep clinical trial programs behind the identical molecule (semaglutide, prescribed under approved trade formulations, is chemically the same peptide sold research-grade elsewhere); others have never been given to a human being on purpose.

The honest question to ask of any peptide is not 'is it a research peptide' but 'what, specifically, has been tested, in whom, and how many times.' A single mouse study is not the same claim as a 17,000-person cardiovascular outcomes trial, even though both can be summarized in a sentence that sounds equally confident. This desk tries to keep those sentences distinguishable.

Mapping three metabolic peptides, plainly

The organizing idea here is the metabolic research peptides, plainly mapped — three compounds, three different evidence tiers, laid out without smoothing over the gaps.

Semaglutide sits at the top of the ladder: a GLP-1 receptor agonist with FDA approval across type 2 diabetes, weight management, and cardiovascular-risk reduction, backed by trials running into the tens of thousands of participants ^[8][9]. It is also, notably, the compound that lost a direct head-to-head efficacy comparison to a newer dual agonist, which is worth knowing before treating 'approved' as a synonym for 'best in class' ^[6].

Tesamorelin is a GHRH analogue with a single narrow FDA approval — reducing visceral fat in HIV-associated lipodystrophy ^[14][15]. Its mechanism (stimulating the body's own growth-hormone pulses rather than supplying growth hormone directly) is well characterized in healthy volunteers ^[16], but nearly everything said about it for other purposes is extrapolation from that one indication, not a separately tested claim.

MOTS-c is the frontier case: a mitochondrial-encoded peptide with a genuinely interesting mechanism — it appears to bind casein kinase 2 directly and to regulate nuclear gene expression under metabolic stress ^[1][5] — and almost no human interventional evidence. The strongest human data point is a single observational cohort in hemodialysis patients that associates naturally circulating MOTS-c with outcomes; it says nothing about what injecting exogenous MOTS-c would do ^[2].

Reading the three side by side is the point of this desk. See the comparison page for the tier-by-tier breakdown.

A note on how this desk weighs evidence

Three rules govern what gets said here. First, a single study is flagged as a single study — a Phase 2 trial in a few hundred people, however encouraging, is not treated as settled science, and neither is a mouse experiment. Second, human and animal data are not blended into one sentence; when a claim comes from rodents, this site says rodents. Third, an FDA approval is reported for exactly the indication it covers and no further — tesamorelin's approval for HIV-associated lipodystrophy does not transfer to general fat loss, and it is not described as though it does.

This produces a less reassuring read than most peptide marketing copy, and that is the intent. The aim is a reader who finishes a page on this site knowing precisely how far the evidence for that compound actually reaches — not further, and not less.